1093 Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
CSPC Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.27 |
| 52 Week High | HK$7.83 |
| 52 Week Low | HK$4.27 |
| Beta | 0.64 |
| 1 Month Change | 9.11% |
| 3 Month Change | 21.15% |
| 1 Year Change | -11.28% |
| 3 Year Change | -38.07% |
| 5 Year Change | -38.30% |
| Change since IPO | 1,149.19% |
Recent News & Updates
Recent updates
CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 04
An Intrinsic Calculation For CSPC Pharmaceutical Group Limited (HKG:1093) Suggests It's 47% Undervalued
Mar 07CSPC Pharmaceutical Group Limited's (HKG:1093) Share Price Not Quite Adding Up
Feb 10Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?
Nov 15Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22Shareholder Returns
| 1093 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.7% | -6.2% | -6.7% |
| 1Y | -11.3% | 10.9% | 15.8% |
Return vs Industry: 1093 underperformed the Hong Kong Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: 1093 underperformed the Hong Kong Market which returned 15.8% over the past year.
Price Volatility
| 1093 volatility | |
|---|---|
| 1093 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1093 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1093's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 21,400 | Cuilong Zhang | www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Limited Fundamentals Summary
| 1093 fundamental statistics | |
|---|---|
| Market cap | HK$60.49b |
| Earnings (TTM) | HK$4.61b |
| Revenue (TTM) | HK$30.90b |
13.1x
P/E Ratio2.0x
P/S RatioIs 1093 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1093 income statement (TTM) | |
|---|---|
| Revenue | CN¥29.01b |
| Cost of Revenue | CN¥8.71b |
| Gross Profit | CN¥20.30b |
| Other Expenses | CN¥15.97b |
| Earnings | CN¥4.33b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.38 |
| Gross Margin | 69.97% |
| Net Profit Margin | 14.92% |
| Debt/Equity Ratio | 1.2% |
How did 1093 perform over the long term?
See historical performance and comparisonDividends
4.9%
Current Dividend Yield66%
Payout RatioDoes 1093 pay a reliable dividends?
See 1093 dividend history and benchmarks| CSPC Pharmaceutical Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 04 2025 |
| Dividend Pay Date | Jul 18 2025 |
| Days until Ex dividend | 51 days |
| Days until Dividend pay date | 95 days |
Does 1093 pay a reliable dividends?
See 1093 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 12:07 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CSPC Pharmaceutical Group Limited is covered by 50 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sharon Shi | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Ethan Cui | BofA Global Research |